Abstracts tagged "Access to care"

Abstract Number: 1260 • ACR Convergence 2021
Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus
Prarthana Jain¹, Mithu Maheswaranathan², Holly Mitchell³ and Diane Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²Duke University School of Medicine, Durham, NC, ³Ralph H Johnson VA Medical Center, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by episodes of flares, often involving multiple organ systems. Medication nonadherence remains a significant problem,…
Abstract Number: L05 • ACR Convergence 2020
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
Kaleb Michaud¹, Sofia Pedro², Kristin Wipfler³, Ekta Agarwal⁴ and Patricia Katz⁵, ¹University of Nebraska Medical Center and Forward, the National Databank for Rheumatic Diseases, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Pfizer inc, Princeton Jct, NJ, ⁵UCSF, Mill Valley, CA
Background/Purpose: To understand medication and clinical care changes by patients with RA during the first 3 months (March through May 2020) of the COVID-19 pandemic…
Abstract Number: 0004 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases: A Study in 15 Arab Countries
Nelly Ziade¹, Lina El Kibbi², Ihsane Hmamouchi³, Nizar Abdulateef⁴, Hussein Halabi⁵, Wafa Hamdi⁶, Fatemah Abutiban⁷, Manal el Rakawi⁸, Mervat Eissa⁹ and Basel Masri¹⁰, ¹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ²Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ³Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ⁴Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ⁵King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁶Department of Rheumatology, Kassab Institute of orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia, Tunis, Tunisia, ⁷Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ⁸Departement of Rheumatology, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, Blida, Algeria, ⁹Rheumatology Department, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Jordan Hospital, Amman, Jordan, Amman, Jordan
Background/Purpose: To evaluate the impact of the Coronavirus Disease 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases in…
Abstract Number: 0575 • ACR Convergence 2020
The Impact of an Integrated Care Management Program on Acute Care Utilization and Outpatient Appointment Attendance Among High-Risk Patients with Lupus
Jessica Williams¹, Weixing Huang², Jamie Collins³, Kreager Taber¹, Katherine McLaughlin¹, Rebecca Cunningham¹, Christine Vogeli⁴, Lisa Wichmann¹ and Candace Feldman³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are often members of disadvantaged groups and some struggle with high acute care utilization and missed outpatient appointments.…
Abstract Number: 1301 • ACR Convergence 2020
Characterizing How SLE Patients Access Health Information Pre and During COVID-19
Francesca Cardwell¹, Susan Elliott², May Choi³, Ricky Chin⁴ and Ann Clarke⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Calgary, Calgary, Canada
Background/Purpose: The spread of misinformation related to COVID-19 has been especially acute for SLE patients as unsubstantiated claims regarding the efficacy of antimalarials for COVID-19…
Abstract Number: 0007 • ACR Convergence 2020
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Emily Sirotich¹, Kevin Kennedy², Salman Surangiwala³, Teresa Semalulu¹, Maggie Larche¹, Jean Liew⁴, Zachary Wallace⁵, Philip Robinson⁶, Rebecca Grainger⁷, Jeffrey Sparks⁸, Julia Simard⁹, Jinoos Yazdany¹⁰, Monique Gore-Massy¹¹, Richard Howard¹², Mitchell Levine² and Jonathan Hausmann¹³, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴University of Washington, Seattle, WA, ⁵Massachusetts General Hospital, Newton, MA, ⁶University of Queensland, Herston, Queensland, Australia, ⁷University of Otago, Wellington, New Zealand, ⁸Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁹Stanford Medicine, Stanford, CA, ¹⁰UCSF, San Francisco, CA, ¹¹Lupus Foundation of America, Brooklyn, NY, ¹²Spondylitis Association of America, Van Nuys, CA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…
Abstract Number: 0576 • ACR Convergence 2020
Medical Savings of Timely Rheumatoid Arthritis Diagnoses
Kathryn Johnson¹, Christine Sawicki¹, Cristina Sotelo², Tanvi Kalevar³, Sylvie Lardeux⁴, Fabio Casadio³, David Baghdadi⁵, Michele Hamburger⁶, Elisea Avalos-Reyes⁷ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Austin, TX, ³CVS Health, New York, NY, ⁴CVS Health, Wellesley, MA, ⁵CVS Health, Woonsocket, RI, ⁶Frances Hamburger Institute, Hauppauge, NY, ⁷CVS Health, Irving, TX
Background/Purpose: Previous studies suggest that early rheumatoid arthritis (RA) recognition and treatment provides greater clinical benefits than treatment started later in the disease course. However,…
Abstract Number: 1316 • ACR Convergence 2020
Patient Perceptions of Fibromyalgia Symptoms and the Overlap with Axial Spondyloarthritis
Kelly Gavigan¹, William Nowell², Regan Reynolds¹, Laura Stradford¹, Jeffrey R Curtis³ and Alexis Ogdie⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, New York City, NY, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: In clinical practice, it is often challenging to distinguish fibromyalgia syndrome (FMS) from axial spondyloarthritis (axSpA), which includes ankylosing spondylitis and non-radiographic axSpA. Early stages…
Abstract Number: 0012 • ACR Convergence 2020
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Kristin Wipfler¹, Yomei Shaw², Teresa Simon³, Adam Cornish¹, Bryant England⁴, Alexis Ogdie⁵, Patricia Katz⁶ and Kaleb Michaud⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, East Lansing, MI, ³Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, Novato, CA
Background/Purpose: Patients with rheumatic diseases such as RA and lupus have increased risk of infection and are treated with medications that may increase this risk…
Abstract Number: 0577 • ACR Convergence 2020
Qualitative Review of Unsuccessful Pilot Study of Super-Utilizer Systemic Lupus Erythematosus (SLE) Patients Enrollment into Team Based Program to Improve Patient Outcomes
Sarah Min¹, Devy Setyono², Sunghye Kim³, Feben Girma¹, Melanie Martin¹ and Rachel Wolfe¹, ¹Wake Forest Baptist Medical Center, Winston-Salem, NC, ²Emkey Arthritis and Osteoporosis Clinic, Wyomissing, PA, ³W.G. Hefner VA Medical Center, Salisbury, NC
Background/Purpose: SLE is a chronic multi-system autoimmune disease, affecting mostly women of child-bearing age and more racial minorities, with a wide spectrum of outcomes: from…
Abstract Number: 1584 • ACR Convergence 2020
Telemedicine Visits During COVID-19 Improved Clinic Show Rates
Reem Alkilany¹ and Raymond Hong², ¹MetroHealth medical center, lakewood, OH, ²Metrohealth Medical center, Richfield, OH
Background/Purpose: The COVID-19 pandemic has tremendously affected the healthcare sector. State of Ohio officials recommended to hold in-person outpatient visits and elective procedures to limit…
Abstract Number: 0017 • ACR Convergence 2020
Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications
Daniel Watrous¹, Glenn Parris², Priya Reddy³, Jeffrey Alper⁴, Fenglong Xie⁵, Maria (Maio) Danila⁶, Michael George⁷, William Nowell⁸, Joel Kallich⁹ and Jeffrey R Curtis¹⁰, ¹Sierra Pacific Arthritis, Visalia, CA, ²PARRIS & ASSOCIATES, Lilburn, GA, ³Southwest Florida Rheumatology, Riverview, FL, ⁴Medallion Clinical Research Institute, LLC, Naples, FL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Global Healthy Living Foundation, New York City, NY, ⁹Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ¹⁰Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The global COVID19 pandemic has had a major impact on healthcare. The effect on rheumatology patients and providers is unclear, as is the role…
Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Guy Cozzi¹, Pavlo Kyrychenko², Michele Hamburger³ and Elisea Avalos-Reyes⁴, ¹CVS Health, Northbrook, IL, ²CVS Health, Norhtbrook, IL, ³Frances Hamburger Institute, Hauppauge, NY, ⁴CVS Health, Irving, TX
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…
Abstract Number: 1585 • ACR Convergence 2020
Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic
Julie Thomas¹, Dorota Lebiedz-Odrobina¹, Kyle Register¹, Francesca Ferrara¹, Danielle Barlow¹, Alicia Riddle¹ and Karla Miller², ¹University of Utah, Salt Lake City, UT, ²Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic created an urgent need for access to care while preserving patient safety through social distancing. Prior to the pandemic, patients were…
Abstract Number: 0019 • ACR Convergence 2020
Lasting COVID-19 Impacts on US Rheumatology Practices
Lynn Price¹, Gianna Melendez¹ and Phil Pouliot¹, ¹spherix global insights, Exton, PA
Background/Purpose: In late 2019, a novel, highly contagious coronavirus (COVID-19), was discovered in China and quickly spread throughout the world, equating to arguably the largest…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.